Local
Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Source: Ventura County Reporter

The opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is Innovent's first European regulatory milestone; if approved, Zybrivo would expand first-line treatment options for eligible patients with lung cancer in Europe
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Ventura County Reporter



